ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2006
Childhood's gliosarcomas: pathological and therapeutical considerations on three cases and critical review of the literature.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Pediatric gliosarcoma, a rare central nervous system tumor in children: Case report and literature review.Heliyon · 2023Article
- Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature.BMC pediatrics · 2021Review
- Gliosarcoma in a Young Filipino Woman: A Case Report and Review of the Literature.The American journal of case reports · 2019Review
- Dural masses: meningiomas and their mimics.Insights into imaging · 2019Review
- Spinal cord gliosarcoma with rhabdomyoblastic differentiation: a case report.International journal of clinical and experimental pathology · 2017Article
- Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature.World journal of clinical cases · 2016Article
- Therapeutic management of gliosarcoma in the temozolomide era.CNS oncology · 2015Review
- Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.Journal of pediatric hematology/oncology · 2014Article
- Clinical and epidemiological characteristics of pediatric gliosarcomas.Journal of neuro-oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliosarcoma is a rare cerebral tumor that has only recently been classified as a separate clinico-pathological entity, even though it remains closely related to glioblastoma in terms of both its clinical and therapeutic characteristics. The onset of this tumor during childhood is particularly unusual. DISCUSSION: The authors describe three cases of gliosarcoma in three patients of 13, 15, and 16 years old, in an attempt to identify any distinctive aspects of the "juvenile" variety. On the basis of their personal experience and in the light of the available literature, the authors review the salient features of this pathological condition in young patients to identify any distinctive aspects as well as to define the significance of the extent of the sarcomatous component and of a "meningioma-like" appearance of the lesion, in terms of survival.
conclusionIn particular, they emphasize how modern diagnostic-therapeutic protocols make it possible to achieve a massive cytoreduction of the lesion in absolute safety in many cases, while avoiding further deficits in others, thus ensuring not only significant survival times but also a good quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.